Critical Analysis: Kyntra Bio (KYNB) & Its Rivals

Kyntra Bio (NASDAQ:KYNB) is one of 456 publicly-traded companies in the “Pharmaceutical Preparations” industry, but how does it compare to its competitors? We will compare Kyntra Bio to related companies based on the strength of its risk, dividends, analyst recommendations, earnings, institutional ownership, profitability and valuation.

Earnings & Valuation

This table compares Kyntra Bio and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Kyntra Bio	$29.62 million	-$47.58 million	0.14
Kyntra Bio Competitors	$433.49 million	-$67.98 million	-10.71

Kyntra Bio’s competitors have higher revenue, but lower earnings than Kyntra Bio. Kyntra Bio is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

Kyntra Bio has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Comparatively, Kyntra Bio’s competitors have a beta of 5.47, meaning that their average stock price is 447% more volatile than the S&P 500.

Institutional and Insider Ownership

72.7% of Kyntra Bio shares are held by institutional investors. Comparatively, 39.1% of shares of all “Pharmaceutical Preparations” companies are held by institutional investors. 2.0% of Kyntra Bio shares are held by insiders. Comparatively, 13.8% of shares of all “Pharmaceutical Preparations” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Kyntra Bio and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	1	1	0	0	1.50
Kyntra Bio Competitors	4894	9963	15988	376	2.38

As a group, “Pharmaceutical Preparations” companies have a potential upside of 70.51%. Given Kyntra Bio’s competitors stronger consensus rating and higher possible upside, analysts clearly believe Kyntra Bio has less favorable growth aspects than its competitors.

Profitability

This table compares Kyntra Bio and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,598.55%	N/A	-26.27%
Kyntra Bio Competitors	-2,662.14%	-363.93%	-42.95%

Summary

Kyntra Bio competitors beat Kyntra Bio on 7 of the 13 factors compared.

About Kyntra Bio

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.